Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Actin-related protein 5 (Arp5)
- Target
- Arp5
- Molecular classification
- Actin family protein, Chromatin remodeling complex component (subunit of INO80 complex), Structural nuclear protein, Other (nuclear actin-related protein)
01
Overview
Actin-related protein 5 (Arp5), encoded by the ACTR5 gene, is a nuclear-localized actin-like protein and a subunit of the INO80 chromatin remodeling complex. ARP5 regulates nucleosome movement and chromatin accessibility, thus impacting gene expression, DNA repair, and replication. It also has INO80-independent roles, such as direct interaction with and inhibition of key myogenic transcription factors (e.g., MyoD and MyoG) during muscle differentiation. ARP5 is upregulated in certain cancers (notably rhabdomyosarcoma) and its overexpression in muscle cells leads to defective differentiation and muscle atrophy, while its knockdown restores differentiation and reduces tumorigenic characteristics. ARP5 is therefore an important regulatory molecule in epigenetic control of differentiation and disease processes[2][4].
- Other names
- ARP5ACTR5Actin-like protein 5
02
Mechanism of action
No drugs with defined mechanisms targeting ARP5 are presently described; functional modulation is currently via genetic or molecular biology approaches (e.g., gene knockdown/overexpression in experimental models)[2][4].
03
Biological functions
Regulation of chromatin remodeling (via INO80 complex)Regulation of gene expression (influences myogenic regulatory factors such as MyoD and MyoG)Nucleosome slidingNegative regulation of myogenic differentiationRegulation of vascular smooth muscle cell phenotypeDNA repair (associated with chromatin accessibility and double-strand break repair)
04
Disease associations
Cancer (notably rhabdomyosarcoma, with upregulation contributing to tumorigenic processes)Muscle atrophy (excess ARP5 causes skeletal muscle atrophy in animal models)Impaired skeletal muscle differentiationOther: Potential roles in smooth muscle disorders and proliferation/differentiation phenotypesNo common links to infection, cardiovascular disease, or neurodegeneration were found in current sources.
05
Safety considerations
Overexpression can inhibit differentiation and cause muscle atrophy[2][4]Potential impact on proliferation/differentiation balance in both cancer and muscle disorders[2][4]Involved in chromatin remodeling, so targeting may have broad nuclear effects and pleiotropic risks
06
Biomarkers
Upregulation of ARP5: Possible biomarker for rhabdomyosarcoma and its myogenic dysregulationDownregulation: Associated with normal differentiation in skeletal and smooth muscle[2][4]
Beyond the preview
Go deeper on Actin-related protein 5 (Arp5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Actin-related protein 5 (Arp5).